PriceTracker GLP-1

What FDA’s record states

FDA record for the warning letter to Dripgym Mobile Parent, LLC dba Amp Health
FieldWhat FDA’s record statesSource
RecipientDripgym Mobile Parent, LLC dba Amp HealthFDA letter
LocationLos Angeles, CAFDA letter
Letter dateFeb 20, 2026FDA letter
Posted by FDAMar 3, 2026FDA index
Issuing officeCenter for Drug Evaluation and Research (CDER)FDA letter
SubjectFalse & Misleading Claims/Misbranded (Telehealth)FDA letter
MARCS-CMS number717992FDA letter
GLP-1 drugs namedSemaglutide, TirzepatideFDA letter
Response letterNot published by FDAFDA letter
Closeout letterNot published by FDAFDA letter
“The compounded semaglutide and tirzepatide products displayed on your website identify “Amp Health” on the pictured label, suggesting Amp Health is the compounder of those drugs when in fact it is not.2 Accordingly, the representations on your website that Amp Health is the compounder of these drug products are false or misleading, and the products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].”FDA warning letter to Dripgym Mobile Parent, LLC dba Amp Health, Feb 20, 2026 · read the full letter on fda.gov ↗

What this is and is not.A warning letter is FDA’s statement of what it considers significant violations. It is an allegation, not a court finding, and the firm can respond. A closeout letter is posted when FDA confirms the violations were corrected.

Other GLP-1 letters FDA issued that week

And 17 more in the full list.

Source

Every field above is copied from FDA’s page for this letter, read Oct 3, 2026. The letter on fda.gov ↗ · All 161 GLP-1 warning letters